Final progression-free survival analysis of JUPITER-02, a randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma.

被引：0

作者：

Mai, Hai-Qiang ^{[1
]}

Chen, Qiu-Yan ^{[1
]}

Chen, Dongping ^{[2
]}

Hu, Chaosu ^{[3
]}

Yang, Kunyu ^{[4
]}

Wen, Jiyu ^{[5
]}

Li, Jingao ^{[6
]}

Shi, Yingrui ^{[7
,8
]}

Jin, Feng ^{[9
]}

Xu, Ruilian ^{[10
]}

Pan, Jianji ^{[11
]}

Qu, Shenhong ^{[12
]}

Li, Ping ^{[13
]}

Hu, Chunhong ^{[14
]}

Liu, Yi-Chun ^{[15
]}

Jiang, Yi ^{[16
]}

He, Xia ^{[17
]}

Wang, Hung-Ming ^{[18
]}

Lim, Wan-Teck ^{[19
]}

Xu, Rui-Hua ^{[1
]}

机构：

[1] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China

[2] Guangzhou Med Univ, Affiliated Canc Hosp & Inst, Guangzhou, Peoples R China

[3] Fudan Univ, Ctr Canc, Shanghai, Peoples R China

[4] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Wuhan, Peoples R China

[5] Affiliated Hosp Guangdong Med Univ, Zhanjiang, Peoples R China

[6] Jiangxi Canc Hosp, Nanchang, Jiangxi, Peoples R China

[7] Xiangya Sch Med, Hunan Canc Hosp, Changsha, Peoples R China

[8] Xiangya Sch Med, Affiliated Canc Hosp, Changsha, Peoples R China

[9] Guizhou Med Univ, Guizhou Canc Hosp, Guiyang, Peoples R China

[10] Shenzhen Peoples Hosp, Shenzhen, Peoples R China

[11] Fujian Prov Canc Hosp, Fuzhou, Peoples R China

[12] Peoples Hosp Guangxi Zhuang Autonomous Reg, Nanning, Peoples R China

[13] Sichuan Univ, West China Hosp, Chengdu, Peoples R China

[14] Cent South Univ, Xiangya Hosp 2, Changsha, Peoples R China

[15] Taichung Vet Gen Hosp, Taichung, Taiwan

[16] Canc Hosp Shantou Univ, Coll Med, Shantou, Peoples R China

[17] Jiangsu Canc Hosp, Nanjing, Peoples R China

[18] Chang Gung Mem Hosp, Taoyuan, Taiwan

[19] Natl Canc Ctr, Singapore, Singapore

来源：

CANCER RESEARCH | 2022年 / 82卷 / 12期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT226

引用

页数：2

共 50 条

[1] JUPITER-02: Randomized, double-blind, phase III study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).
Xu, Rui-Hua
Mai, Hai-Qiang
Chen, Qiu-Yan
Chen, Dongping
Hu, Chaosu
Yang, Kunyu
Wen, Jiyu
Li, Jin-Gao
Shi, Yingrui
Jin, Feng
Xu, Ruilian
Pan, Jianji
Qu, Shenhong
Li, Ping
Hu, Chunhong
Liu, Yi-Chun
Jiang, Yi
He, Xia
Wang, Hung-Ming
Lim, Wan-Teck
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (18)
[2] Final overall survival analysis of JUPITER-02: A phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).
Mai, Hai-Qiang
Chen, Qiu-Yan
Chen, Dong-Ping
Hu, Chaosu
Yang, Kunyu
Wen, Jiyu
Li, Jin-Gao
Shi, Yingrui
Jin, Feng
Xu, Ruilian
Pan, Jian-Ji
Qu, Shenhong
Li, Ping
Hu, Chunhong
Liu, Yi-Chun
Jiang, Yi
He, Xia
Wang, Hung-Ming
Lim, Darren Wan-Teck
Xu, Rui-Hua
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[3] GEM20110714: Final overall survival results of the phase III study of first-line gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma.
Hong, Shaodong
Huang, Yan
Yang, Yunpeng
Yu, Gengsheng
Jia, Jun
Peng, Jiewen
Lin, Qing
Xi, Xuping
Peng, Peijian
Chen, Dongping
Xu, Mingjun
Lu, Xiaojun
Zhang, Li
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[4] Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study
Hong, Shaodong
Zhang, Yaxiong
Yu, Gengsheng
Peng, Peijian
Peng, Jiewen
Jia, Jun
Wu, Xuan
Huang, Yan
Yang, Yunpeng
Lin, Qing
Xi, Xuping
Xu, Mingjun
Chen, Dongping
Lu, Xiaojun
Wang, Rensheng
Cao, Xiaolong
Chen, Xiaozhong
Lin, Zhixiong
Xiong, Jianping
Lin, Qin
Xie, Conghua
Li, Zhihua
Pan, Jianji
Li, Jingao
Wu, Shixiu
Lian, Yingni
Yang, Quanlie
Zhao, Chong
Fang, Wenfeng
Zhang, Li
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (29) : 3273 - +
[5] Camrelizumab versus placebo combined with gemcitabine and cisplatin for recurrent or metastatic nasopharyngeal carcinoma: A randomized, double-blind, phase 3 trial.
Zhang, Li
Yang, Yunpeng
Qu, Song
Li, Jin-Gao
Hu, Chaosu
Xu, Mingjun
Li, Weidong
Zhou, Ting
Shen, Liangfang
Wu, Hui
Lang, Jin Yi
Hu, Guangyuan
Luo, Zhanxiong
Fu, Zhichao
Qu, Shenhong
Zhang, Ben
Yang, Qing
Zhang, Xiaojing
Zou, Jianjun
Fang, Wenfeng
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[6] Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial
Yang, Yunpeng
Qu, Song
Li, Jingao
Hu, Chaosu
Xu, Mingjun
Li, Weidong
Zhou, Ting
Shen, Liangfang
Wu, Hui
Lang, Jinyi
Hu, Guangyuan
Luo, Zhanxiong
Fu, Zhichao
Qu, Shenhong
Feng, Weineng
Chen, Xiaozhong
Lin, Shaojun
Zhang, Weimin
Li, Xiaojiang
Sun, Yan
Lin, Zhixiong
Lin, Qin
Lei, Feng
Long, Jianting
Hong, Jinsheng
Huang, Xiaoming
Zeng, Lingzhi
Wang, Peiguo
He, Xiaohui
Zhang, Ben
Yang, Qing
Zhang, Xiaojing
Zou, Jianjun
Fang, Wenfeng
Zhang, Li
LANCET ONCOLOGY, 2021, 22 (08): : 1162 - 1174
[7] Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial
Mai, Hai-Qiang
Chen, Qiu-Yan
Chen, Dongping
Hu, Chaosu
Yang, Kunyu
Wen, Jiyu
Li, Jingao
Shi, Ying-Rui
Jin, Feng
Xu, Ruilian
Pan, Jianji
Qu, Shenhong
Li, Ping
Hu, Chunhong
Liu, Yi-Chun
Jiang, Yi
He, Xia
Wang, Hung-Ming
Lim, Wan-Teck
Liao, Wangjun
He, Xiaohui
Chen, Xiaozhong
Liu, Zhigang
Yuan, Xianglin
Li, Qi
Lin, Xiaoyan
Jing, Shanghua
Chen, Yanju
Lu, Yin
Hsieh, Ching-Yun
Yang, Muh-Hwa
Yen, Chia-Jui
Samol, Jens
Feng, Hui
Yao, Sheng
Keegan, Patricia
Xu, Rui-Hua
NATURE MEDICINE, 2021, 27 (09) : 1536 - +
[8] Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial
Hai-Qiang Mai
Qiu-Yan Chen
Dongping Chen
Chaosu Hu
Kunyu Yang
Jiyu Wen
Jingao Li
Ying-Rui Shi
Feng Jin
Ruilian Xu
Jianji Pan
Shenhong Qu
Ping Li
Chunhong Hu
Yi-Chun Liu
Yi Jiang
Xia He
Hung-Ming Wang
Wan-Teck Lim
Wangjun Liao
Xiaohui He
Xiaozhong Chen
Zhigang Liu
Xianglin Yuan
Qi Li
Xiaoyan Lin
Shanghua Jing
Yanju Chen
Yin Lu
Ching-Yun Hsieh
Muh-Hwa Yang
Chia-Jui Yen
Jens Samol
Hui Feng
Sheng Yao
Patricia Keegan
Rui-Hua Xu
Nature Medicine, 2021, 27 : 1536 - 1543
[9] A multicenter, randomized, double-blind, placebo-controlled phase Ill study of anlotinib or placebo in combination with gemcitabine and cisplatin (GP) as first -line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC).
Yang, Yunpeng
Huang, Yan
Fang, Wenfeng
Ma, Yuxiang
Cai, Qingqing
Li, Zhi-Ming
Zhao, Hongyun
Zhao, Yuanyuan
Zhou, Ting
Hong, Shaodong
Zhang, Yaxiong
Zhang, Li
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[10] Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma
Chen, Xudong
Liang, Weiting
Wan, Ning
Zhang, Li
Yang, Yunpeng
Jiang, Jie
Zhang, Tiantian
ORAL ONCOLOGY, 2019, 94 : 80 - 85

← 1 2 3 4 5 →